Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy

At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's blockbuster diabetes ​drug Ozempic and weight-loss drug Wegovy over ​the weekend, at globally unmatched prices and slashing treatment costs by about ​70%.

The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.

Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper ‌variants.


Large Indian ⁠drugmakers are ⁠racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of ​the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.

Here is a list ​of Indian drugmakers that have launched generic semaglutide in recent days:

SUN PHARMACEUTICAL

India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from ​0.25 mg to 2.4 mg and Sematrinity in two dose strengths ⁠for type ‌2 diabetes. Noveltreat is expected to cost around Rs 900 to Rs 2000 ($9.58-$21.30) ​for weekly treatment, ​and Sematrinity will cost Rs 750 to 1300 ($7.99-$13.84), the company said.

DR REDDY'S LABORATORIES

The ⁠Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes ​in 2 mg and 4 mg dose strengths in a disposable pen ​device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about Rs 4200 ($44.73) per month, the company said.

ZYDUS LIFESCIENCES

The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately Rs 2,200 ($23.43), the company said.

TORRENT PHARMACEUTICALS

The ‌company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be Rs 3,999 ($42.59) per month, ​the company ​said.

GLENMARK PHARMACEUTICALS Glenmark launched injectable semaglutide, ⁠branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around Rs 1,300 to Rs 1,760 for a month's usage. ($13.84-$18.74).

ALKEM LABORATORIES

The company said its semaglutide, launched under three ​brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at Rs 1,800 ($19.17) per month.

ERIS LIFESCIENCES

The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is Rs 1,290 ($13.74) per month. Eris is also in partnership with Natco Pharma, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.